Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53

International Journal of Cancer

Volumn 72, Issue 1, 1997, Pages 155-159

  Vikhanskaya, Faina ^a   Clerico, Luana ^a   Valenti, Monica ^a   Stanzione, Maria S ^a   Broggini, Massimo ^b   Parodi, Silvio ^a   Russo, Patrizia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ist Ric Farmacologiche Mario Negri   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; MESSENGER RNA; MITOMYCIN C; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG RESISTANCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; ONCOGENE C ERB; OVARY CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CISPLATIN; DNA FRAGMENTATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030745894     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970703)72:1<155::AID-IJC22>3.0.CO;2-H     Document Type: Article

References (29)

1. ALI-OSMAN, F., BERGER, M.G., RAJAGOPAL, S., SPENCE, A. and LIVINGSTON, R.B., Topoisomerase-II inhibition and altered kinetics of formation and repair nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res., 53, 5663-5668 (1993).
2. ANDREWS, P.A., VELURY, S., MANN, S.C. and HOWELL, S.B., Cisdiamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian-carcinoma cells. Cancer Res., 48, 68-73 (1988).
3. BERTRAND, R., KOHN, K.W., SOLARY, E. and POMMIER, Y., Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter-elution assay. Drug Dev. Res., 34, 138-144 (1995).
4. BERTRAND, R. and POMMIER, Y., Assessment of DNA damage in mammalian cells by DNA filter-elution methodology. In: G.P. Studzinski (ed.), Cell growth and apoptosis, Vol. 6, pp. 97-117, Oxford University Press, Newark (1995).
5. BONADONNA, G., MONFARDINI, S., DELENA, N. and FOSSATI-BELLANI, F., Clinical evaluation of adriamycin, a new tumor antibiotic. Brit. Med. J., 3, 503-506 (1969).
6. BROWN, R., CLUGSTON, C., BURNS, P., EDLIN, A., VASEY, P., VOJTESEK, B. and KAYE, S.B., Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55, 678-684 (1993).
7. CARTER, S.K., Adriamycin - a review. J. nat. Cancer Inst., 55, 1265-1274 (1975).
8. CIMOLI, G., VALENTI, M., NOVIELLO, E., PARODI, S., MAZZONI, A., ROVINI, E., DE SESSA, F. and RUSSO, P., "Atypical" multidrug resistance in human ovarian-cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). J. Cancer Res. clin. Oncol., 121, 155-163 (1995).
9. EDER, J.P. JR, CHAN, V.T-W., NG, S-W., RIZVI, N.A., ZACHAROULIS, S., TEICHER, B.A. and SCHNIPPER, L.E., DNA topoisomerase-11 expression is associated with alkylating-agent resistance. Cancer Res., 55, 6109-6116 (1995).
10. ELIOPOULOS, A.G., KERR, D.J., HEROD, J., HODGKINS, L., KRAJEWSKI, S., REED, J.C. and YOUNG, L.S., The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11, 1217-1228 (1995).
11. ERCOLANI, L., FLORENCE, B., DENARO, M. and ALEXANDER, M., Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate-dehydrogenase gene. J. biol. Chem., 263, 15335-15341 (1988).
12. FAN, S., SMITH, M.L., RIVET II, D.J., DUBA, D., ZHAN, Q., KOHN, K.W., FORNACE, A.J. JR. and O'CONNOR, P.M., Disruption of p53 function sensitizes breast-cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
13. FEUDIUS, P., DEBERNARDIS, D., BECCAGLIA, P., VALENTI, M., GZANIELA, SIZÉ, E., AZZANI, D., STANZIONE, S., PAZODI, S., D'INCALCI, M., RUSSO, P., and BROZZINI, M., DDP-induced cytotoxicity, apoptosis and activation of p53 in human ovarian cancer cell lines with different p53 status. Brit. J. Cancer, (1997).
14. FRAM, J., WODA, B.A., WILSON, J.M. and ROBICHAUD, N., Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon-carcinoma cells. Cancer Res., 50, 72-77 (1990).
15. FRITSCHE, M., HAESSLER, C. and BRANDNER, G., Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agent. Oncogene, 8, 307-318 (1993).
16. GOLDWASSER, F. VALENTI, M., TORRES, R., KOHN, K.W. and POMMIER, Y., Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res., 2, 687-693 (1996).
17. HALL, P., MEEK, D. and LANE, O.P., p53 - integrating the complexity. J. Pathol., 180, 1-5 (1996).
18. LOWE, S.W., RULEY, H.E., JAKS, T. and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell, 74, 957-963 (1993).
19. MAZZONI, A., TRAVE, F., CANTI, G.F. and FRANCO, P., Effect of the tiapamil analog RO11-2933 on cellular sensitivity to anti-tumor drugs in sensitive and multidrug-resistant human ovarian-cancer cells. Anticancer Res., 9, 367-372 (1989).
20. NELSON, W.G. and KASTAN, M.B., DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA-damage response pathways. Mol. Cell Biol., 14(3), 1815-1823 (1994).
21. NOVIELLO, E., ALUIGI, M.G., CIMOLI, G., ROVINI, E., MAZZONI, A., PARODI, S., DE SESSA, E and RUSSO, P., Sister chromatide exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase-II-targeted drugs in sensitive (A2780) and resistant (A2780DX3) human ovarian-cancer cells: correlations with the formation of DNA double-strand breaks. Mut. Res., 311, 21-29 (1994).
22. O'BRIAN, R.M., LUCE, J.K., TALLEY, R.W., GOTTLIEB, J.A., BAKER, L.H. and BONADONNA, G., Phase-II evaluation of adriamycin in human neoplasia. Cancer, 32,4-8 (1973).
23. PEREGO, P., GIAROLA, M., RIGHETTI, S.C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M.A., MIYASHITA, T., REED, J.C. and ZUNINO, F., Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian-carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
24. REED, E. and KOHN, K.W., Platinum analogues. In: B.A. Chabner and J.M. Collins (eds.), Cancer chemotherapy. Principles and practice, pp. 465-490, Lippincott, Philadelphia (1992).
25. SARTORELLI, A.C., HODNICK, W.F., BELCOURT, M.F., TOMASZ, M., HAFFTY, B., FISCHER, J.J. and ROCKWELL, S., Mitomicin C: a prototype bioreductive agent. Oncol. Res., 6, 501-508 (1994).
26. SCHREIBER, E., MATTHIAS, P., MULLER, M.M. and SCHAFFNER, W., Rapid detection of octamer binding proteins with "mini extracts", prepared from a small number of cells. Nucleic Acids Res., 17, 6419 (1989).
27. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53,4164-4168 (1993).
28. TSAI, C-M., CHANG, K-T., Wu, L-H., CHEN, J-Y., GAZDAR, A.F., MITSUDOMI, T., CHEN, M.H. and PERNG, R-P., Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small-cell-lung-cancer cell lines. Cancer Res., 56, 206-209 (1996).
29. VIKHANSKAYA, F., D'INCALCI, M.D. and BROGGINI, M., Decreased cytotoxic effect of doxorubicin in human ovarian-cancer cells expressing wild-type p53 and waf1/cip1 genes. Int. J. Cancer, 61, 397-401 (1995).